Abstract：ObjectiveTo investigate the clinical effect of Capecitabine combined with Thalidomide in the metronomic chemotherapy of advanced colorectal cancer.MethodsFrom February 2016 to March 2016,56 patients who diagnosed with advanced colorectal cancer treated in our hospital were selected as the research objects,and they were divided into the combination group(n=30)and chemotherapy group(n=26)according to random number table method.The combination group were treated with Capecitabine combined with Thalidomide.In the chemotherapy group,Oxaliplatin was injected intravenously on the first day and Leucovorin was injected intravenous from second to fifth days,and 20 days for one cycle.The effects of chemotherapy,therapeutic effect and adverse reactions were compared between the two groups.ResultsThe disease control rate of the patients in the combination group was 76.67%,and in the chemotherapy group was 53.85%,the control rate of the disease was compared between the two groups,and the difference was statistically significant(P＜0.05).The total effective rate of treatment was 80.00%,which was significantly higher than 34.62%in the chemotherapy group,and the difference was statistically significant(P＜0.05).The total incidence of adverse reactions(33.33%)in the combination group was significantly lower than that in the chemotherapy group(92.31%),and the difference was statistically significant(P＜0.05).ConclusionCapecitabine combined Thalidomide in the treatment of advanced colorectal cancer has remarkable efficacy,high safety and low adverse reaction rate,so it is worth using in clinical.
Cortejoso L，López-Fernández LA.Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients[J].Pharmacogenomics，2016，13（10）:1173-1191.
京公网安备 11010502046607号